Braemar’s second-in-command is leaving the company. Tris Simmonds is stepping down from his role as chief operating officer at the UK shipbroker with immediate effect. James Gundy’s Braemar ...

This document outlines the risk management options under consideration for boric acid, its salts and its precursors, which have been proposed to be harmful to the environment and human health. For the ...

Tris Pharma’s opioid alternative has scored a third win in a trio of clinical trials, providing the biotech with the data needed to take the pain relief drug to the FDA this year. The latest ...

A New Jersey-based drug company believes it has enough evidence to seek approval for an experimental, first-of-its-kind pain medication. On Thursday, Tris Pharma released data from a clinical trial of ...

Tris Pharma has announced positive data from two Phase III trials of cebranopadol, as well as positive data from a human abuse potential (HAP) study to compare the therapy against various opioids.

Over the past decades, gene therapy has flourished. The basis of this therapy is focused on the use of exogenous therapeutic nucleic acids (NAs) that have the capacity to modify the expression of ...

The systemic and local immune response in burn patients is often extreme and derailed. As excessive inflammation can damage healthy tissues and slow down the healing process, modulation of ...

The Tuli Research Centre for India Studies has launched an extensive digital archive at www.tuliresearchcentre.org, capturing India's cultural essence through a unique range of artifacts.

Guangdong Engineering Research Center for Advanced Energy Storage Materials, School of Materials Science and Engineering, South China University of Technology, Guangzhou 510641, China ...

Figure 1: Fludarabine leads to a loss of STAT1 activation after cytokine treatment of PBMC. Figure 2: Fludarabine leads to a selective loss of STAT1 protein and mRNA from lymphoid cells.